logo

Biocryst Pharmaceuticals Inc (BCRX)



Trade BCRX now with
  Date
  Headline
7/10/2018 4:09:57 PM Biocryst Pharmaceuticals, Trading Expected To Resume At 4:30 PM ET
7/10/2018 4:04:26 PM BioCryst Pharma Announces Termination Of Merger Agreement With Idera Pharma
7/10/2018 4:03:00 PM Biocryst Pharmaceuticals, Trading Halt Pending News
6/25/2018 6:04:04 AM BioCryst Says Deal On Phase 3 Clinical Trial & Regulatory Requirements For Marketing Authorization Of BCX7353 In Japan
6/5/2018 7:35:25 AM BioCryst Urges Stockholders To Vote Today “FOR” The Merger Transaction With Idera Pharmaceuticals
5/29/2018 8:04:58 AM BioCryst Announces Presentation Of Additional Analyses Of The APeX-1 Clinical Trial Of BCX7353
5/24/2018 1:16:43 PM BioCryst's BCX7353 Receives European Regulatory Designations For Treatment Of Hereditary Angioedema
5/8/2018 6:06:08 AM BioCryst Pharma Q1 Net Loss Widens To $25.8 Mln Or $0.26/shr From $14.2 Mln Or $0.19/shr Last Year
5/1/2018 6:05:03 AM BioCryst Receives European Medicines Agency Approval For ALPIVAB For Influenza
4/10/2018 7:33:07 AM BioCryst And Idera Reschedule Meetings To Vote On Proposed Merger To July 10, 2018
4/2/2018 2:59:44 PM RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals
4/2/2018 8:06:36 AM BioCryst Pharma Files Definitive Proxy Statement In Connection With Pending Merger With Idera Pharmaceuticals
3/26/2018 4:07:40 PM Eyenovia Appoints Kenneth Lee, Charles Mather And Anthony Sunto To Board Of Directors
3/15/2018 6:02:23 AM BioCryst Initiates Phase 3 APeX-2 Trial Of BCX7353 In Patients With Hereditary Angioedema
2/27/2018 8:39:07 AM BioCryst Q4 Total Revenues $3.9 Mln Vs. $9.0 Mln Prior Year
2/27/2018 8:16:17 AM BioCryst And Idera File Preliminary Proxy Statement And Investor Presentation In Connection With Pending Merger
1/5/2018 6:05:32 AM BioCryst Pharma Advances Program Exploring ALK2 Inhibitors For Fibrodysplasia Ossificans Progressiva
1/6/2016 6:06:29 AM Jefferies Is Cutting Biocryst Pharmaceuticals Inc (BCRX) 2016 Estimate To -0.54 From -0.41